Phase 4 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older
- People who are able to give their consent to participate before the trial begins
- People who are willing and able to follow all the requirements of the study
- People who are living with HIV
- People who are pregnant and starting combination HIV treatment (cART) between 12 and 26 weeks of pregnancy
- People who plan to breastfeed after giving birth
Who may not be able to join:
- People who have received combination HIV treatment (cART) at any point in the 6 months before joining
- People who have chronic hepatitis B infection along with signs of liver inflammation affecting certain liver enzymes
- People whose liver enzyme levels (ALT) are significantly above the normal range, or whose liver enzyme and bilirubin levels are both elevated at certain thresholds (confirm with trial site)
- People who have previously had a documented treatment failure with a type of HIV medication called an NNRTI
- People who have had an allergic reaction to any HIV medication in the past
- People who are taking certain other medications that can interfere with how the study drugs are processed by the body — for example, rifampicin, some anti-seizure medications, rifabutin, St John's Wort, mitotane, enzalutamide, or lumacaftor (confirm with trial site for the full list)
- People with certain rare inherited conditions affecting how the body processes sugars — specifically galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption — as one of the study drugs contains lactose
- People who have clinical depression or where a doctor has assessed there may be an increased risk of suicidal thoughts
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Saye Khoo, University of Liverpool
Phone: + 44 151 794 5553
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
AUC of doravirine in pregnant women; Cmax of doravirine in pregnant women; Cmin of doravirine in pregnant women; CL/F of doravirine in pregnant women
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.